Ranibizumab Global Market Report 2026

Ranibizumab is a humanized recombinant monoclonal antibody fragment developed to block the activity of vascular endothelial growth factor A (VEGF-A) in managing various retinal disorders by decreasing abnormal blood vessel formation and fluid leakage in the eye. Its benefit lies in its precise delivery through intravitreal injection, reducing systemic side effects while maintaining and potentially enhancing vision in patients.

The main forms of ranibizumab include single-use prefilled syringes and single-use glass vials. Single-use ranibizumab syringes are intended for one-time use, containing the correct dosage of ranibizumab before distribution, and are discarded after a single injection. They are utilized in conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy (DR), diabetic macular edema (DME), myopic choroidal neovascularization (MCNV), and retinal vein occlusion (RVO), and are distributed through channels such as hospital pharmacies, online pharmacies, and others.

Tariffs have influenced the ranibizumab market by increasing costs associated with imported biologic drug substances, sterile packaging materials, and prefilled syringe components used in intravitreal formulations. These impacts are most evident in hospital pharmacies and ophthalmology clinics across regions dependent on cross-border biologics supply, particularly in Asia-Pacific and emerging markets. Higher tariffs can elevate treatment costs and affect affordability. However, tariffs have also encouraged localized fill-finish operations and regional manufacturing investments, supporting supply security and reducing long-term dependency on imports.

The ranibizumab market research report is one of a series of new reports from The Business Research Company that provides ranibizumab market statistics, including ranibizumab industry global market size, regional shares, competitors with a ranibizumab market share, detailed ranibizumab market segments, market trends and opportunities, and any further data you may need to thrive in the ranibizumab industry. This ranibizumab market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The ranibizumab market size has grown steadily in recent years. It will grow from $2.76 billion in 2025 to $2.87 billion in 2026 at a compound annual growth rate (CAGR) of 4.0%. The growth in the historic period can be attributed to increasing prevalence of age related macular degeneration, clinical validation of anti-vegf therapy efficacy, rising incidence of diabetic retinopathy, improved diagnostic imaging for retinal disorders, early regulatory approvals for ranibizumab.

The ranibizumab market size is expected to see steady growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 3.6%. The growth in the forecast period can be attributed to growth in aging population globally, rising diabetes prevalence worldwide, expanding access to advanced ophthalmic care, increasing adoption of intravitreal injections, ongoing improvements in retinal disease screening programs. Major trends in the forecast period include rising adoption of anti-vegf therapies for retinal diseases, growing preference for prefilled syringe formulations, increasing treatment demand for diabetic eye disorders, expansion of ophthalmology specialty care centers, higher use of long-term maintenance therapy in chronic retinal conditions.

The rising prevalence of eye diseases is anticipated to drive the growth of the ranibizumab market in the coming years. Eye diseases include a variety of conditions that affect the eyes, potentially leading to impaired vision and overall eye health. This increase in eye disease prevalence is attributed to factors such as aging populations, lifestyle changes, and a rise in chronic conditions like diabetes. Ranibizumab is utilized to manage conditions such as age-related macular degeneration and diabetic retinopathy, helping to mitigate vision impairment amid the growing incidence of eye diseases. For example, in August 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that roughly 2.2 billion people globally experience either near or distance vision impairment. Consequently, the increasing prevalence of eye diseases is expected to propel the growth of the ranibizumab market.

Major companies operating in the ranibizumab market are emphasizing cost-effective therapies, such as ranibizumab biosimilars, to manage and prevent vision loss in patients with retinal disorders. A ranibizumab biosimilar is a biologic drug that closely resembles the original ranibizumab but is sold under a different brand name, providing a more affordable option while ensuring comparable efficacy and safety. For example, in April 2024, Formycon AG, a Germany-based biotechnology firm, and Bioeq AG, a Switzerland-based biopharmaceutical company, announced the commercial launch of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This release follows marketing authorization from Health Canada under the brand name Ranopto and Swissmedic under the brand name Ranivisio. FYB201 presents a new, high-quality, effective, and affordable treatment option for patients with severe retinal diseases. It has already proven its value as a cost-effective therapy for patients in the USA and multiple regions of Europe.

In March 2024, Sandoz Group AG, a Switzerland-based manufacturer of generic pharmaceuticals and biosimilars, acquired the CIMERLI business from Coherus BioSciences for an undisclosed sum. Through this acquisition, Sandoz aims to strengthen its presence in the biosimilar market, particularly in ophthalmology, by leveraging Coherus BioSciences' expertise in developing biosimilar versions of drugs such as Ranibizumab, used to treat eye diseases. Coherus BioSciences is a US-based biopharmaceutical company focused on creating biosimilar versions of medications, including Ranibizumab.

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries

North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the ranibizumab market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The ranibizumab market consists of sales of biosimilars, intravitreal injections, and compounded formulations. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Ranibizumab Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses ranibizumab market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for ranibizumab ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The ranibizumab market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Product: Single Use Prefilled Syringe; Single Use Glass Vial
• 2) By Application: Wet Age Related Macular Degeneration (AMD); Diabetic Retinopathy (DR); Diabetic Macular Edema (DME); Myopic Choroidal Neovascularization (MCNV); Retinal Vein Occlusion (RVO)
• 3) By Distribution Channel: Hospital Pharmacies; Online Pharmacies; Other Distribution Channels
• Subsegments:
• 1) By Single Use Prefilled Syringe: 0.3 Ml Syringe; 0.5 Ml Syringe; 1 Ml Syringe; Other Volume Variants
• 2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial; 1.0 Mg Or 0.1 Ml Vial; 2.0 Mg Or 0.2 Ml Vial; Other Volume Variants
• Companies Mentioned: F. Hoffmann-La Roche AG; Genentech Inc.; Bayer AG; Novartis AG; Biocon Limited; Samsung Biologics Co Ltd; Celltrion Healthcare Co Ltd; Formycon AG; Coherus BioSciences Inc; Xbrane Biopharma AB; Alvotech; Stada Arzneimittel AG; Sun Pharmaceutical Industries Ltd; Dr. Reddy's Laboratories Ltd; Cipla Limited; Lupin Limited; Glenmark Pharmaceuticals Limited; Intas Pharmaceuticals Ltd; Enzene Biosciences Ltd; Amman Pharmaceutical Industries
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.